References
- Ahmad I., Rao D.N.: Chemistry and biology of DNA methyltransferases. Crit. Rev. Biochem. Mol. Biol. 5–6, 361–380 (1996)
- Ajroud-Driss S., Christiansen M., Allen J.A., Kessler J.A.: Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy. Mol. Ther. 21, 1279–1286 (2013)
- Agorio C., Schreiber F., Sheppard M., Mastroeni P., Fernandez M., Martinez M.A., Chabalgoity J.A.: Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J. Gene Med. 9, 416–423 (2007)
- Badding M.A., Lapek J.D., Friedman A.E., Dean D.A.: Proteomic and functional analyses of protein-DNA complexes during gene transfer. Mol. Ther. 21, 775–785 (2013)
- Barber G.N.: Cytoplasmic DNA innate immune pathways. Immunol. Rev. 243, 99–108 (2011)
- Bauer A.P., Leikam D., Krinner S., Notka F., Ludwig C., Langst G., Wagner R.: The impact of intragenic CpG content on gene expression. Nucleic Acids Res. 38, 3891–3908 (2010)
- Bishop C.J., Majewski R.L., Guiriba T.–R.M., Wilson D.R., Bhise N.S., Quiñones-Hinojosa A., Green J.J.: Quantification of cellular and nuclear uptake rates of polymeric gene delivery nanoparticles and DNA plasmids via flow cytometry. Acta Biomater. 37, 120–130 (2016)
- Bonamassa B., Hai L., Liu D.: Hydrodynamic gene delivery and its applications in pharmaceutical research. Pharm. Res. 28, 694–701 (2011)
- Broeke A.V., Burny A.: Retroviral vector biosafety: lessons from sheep. J. Biomed. Biotechnol. 1, 9–12 (2003)
- Castagliuolo I., Beggiao E., Brun P., Barzon L., Goussard S., Manganelli R., Grillot-Courvalin C., Palu G.: Engineered E. coli delivers therapeutic genes to the colonic mucosa. Gene. Ther. 12, 1070–1078 (2005)
- Chandler R.J., LaFave M.C., Varshney G.K., Burgess S.M., Venditti C.P.: Genotoxicity in mice following AAV gene delivery: a safety concern for human gene therapy? Mol. Ther. 24, 198–201 (2016)
- Chandler R.J., LaFave M.C., Varshney G.K., Trivedi N.S., Carrillo-Carrasco N., Senac J.S., Wu W., Hoffmann V., Elkahloun A.G., Burgess S.M., Venditti C.P.: Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J. Clin. Invest. 125, 870–880 (2015)
- Chen Z.Y., He C.Y., Meuse L., Kay M.A.: Silemcing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther. 11, 856–864 (2004)
- Cheng X.: DNA modification by methyltransferases. Curr. Opin. Struct. Biol. 5, 4–10 (1995)
- Collier J.: Epigenetic regulation of the bacterial cell cycle. Curr. Opin. Microbiol. 12, 722–729 (2009)
- Costa D., Valente A.J.M., Miguel M.G., Queiroz J.: Plasmid DNA hydrogels for biomedical applications. Adv. Colloid Interface Sci. 205, 257–264 (2014)
- Costa D., Valente A.J.M., Miguel M.G., Queiroz J.: Plasmid DNA microgels for drug/gene co-delivery: A promising approach for cancer therapy. Colloids and Surfaces A: Physicochem. Eng. Aspects, 442, 181–190 (2014)
- Darquet A.M., Cameron B., Wils P., Scherman D., Crouzet J.: A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 4, 1341–1349 (1997)
- Darquet A.M., Rangara R., Kreiss P., Schwartz B., Naimi S., Delaère P., Crouzet J., Scherman D.: Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther. 6, 209–218 (1999)
- Dauty E., Verkman A.S.: Actin cytoskeleton as the principal determinant of size-dependent DNA mobility in cytoplasm: a new barrier for non-viral gene delivery. J. Biol. Chem. 280, 7823–7828 (2005)
- Deaton A.M., Bird A.: CpG islands and the regulation of transcription. Genes Dev. 25, 1010–1022 (2011)
- Donsante A., Vogler C., Muzyczka N., Crawford J.M., Barker J., Flotte T., Campbell-Thompson M., Daly T., Sands M.S.: Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 8, 1343–1346 (2001)
- Edelstein M.L., Abedi M.R., Wixon J.: Gene therapy clinical trials worldwide to 2007 – an update. J. Gene Med. 9, 833–842 (2007)
- Edelstein M.L., Abedi M.R., Wixon, J., Edelstein R.M.: Gene therapy clinical trials worldwide 1989–2004 – an overview. J. Gene Med. 6, 597–602 (2004)
- Ehrhardt A., Haase R., Schepers A., Deutsch M.J., Lipps H.J., Baiker A.: Episomal vectors for gene therapy. Curr. Gene Ther. 8, 147–161 (2008)
- European Pharmacopea 8.0., Chapter 5.14. 705–716 (2014)
- Escors D., Breckpot K.: Lentiviral vectors in gene therapy: their current status and future potential. Arch. Immunol. Ther. Exp. (Warsz.), 58, 107–119 (2010)
- European Medicines Agency (EMEA): Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products. Doc. Ref. EMEA/273974/2005, (2005)
- Faurez F., Dory D., Le Moigne V., Gravier R., Jestin A.: Biosafety of DNA vaccines: new generation of DNA vectors and current knowledge on the fate of plasmid after injection. Vaccine, 28, 3888–3895 (2010)
- Gardlik R., Behuliak M., Palffy R., Celec P., Li C.J.: Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther. 18, 425–431 (2011)
- Gaspar V., de Melo-Diogo D., Costa E., Moreira A., Queiroz J., Pichon C., Correia I., Sousa F.: Minicircle DNA vectors for gene therapy: advances and applications. Expert Opin. Biol. Ther. 15, 353–379 (2015)
- Gene Therapy Clinical Trials Worldwide, http://www.wiley.com//legacy/wileychi/genmed/clinical/ (28.10.2016)
- Ginn S.L., Alexander I.E., Edelstein M.L., Abedi M.R., Wixon J.: Gene therapy clinical trials worldwide to 2012 – an update. J. Gene Med. 15, 65–77 (2013)
- Giacca M., Zacchigna S.: VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther. 19, 622–629 (2012)
- Golzio M., Teissie J., Rols M-P.: Direct visualization at the single-cell level of electrically mediated gene delivery. Proc. Natl. Acad. Sci. USA, 99, 1292–1297 (2002)
- Gravier R., Dory D., Laurentie M., Bougeard S., Cariolet R., Jestin A.: In vivo tissue distribution and kinetics of a pseudorabies virus plasmid DNA vaccine after intramuscular injection in swine. Vaccine, 25, 6930–6938 (2007)
- Gromova E.S., Khoroshaev A.V.: Prokaryotic DNA methyltransferases: the structure and the mechanism of interaction with DNA. Mol. Biol. 37, 260–272 (2003)
- Hacein-Bey-Abina, S., Cavazzana-Calvo, M. i wsp.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415–419 (2003)
- Hartmann G., Krieg A.M.: Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164, 944–953 (2000)
- Henry T.D., Hirsch A.T., Goldman J., Wang Y.L., Lips D.L., McMillan W.D., Duval S., Biggs T.A., Keo H.H.: Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Ther. 18, 788–794 (2011)
- Hernando-Herraez I., Garcia-Perez R., Sharp A.J., Marques-Bonet T.: DNA methylation: insights into human evolution. PLoS Genet. DOI:10.1371/journal.pgen.1005661 (2015)
- Hoare T.R, Kohane D.S.: Hydrogels in drug delivery: Progress and challenges. Polymer, 49, 1993–2007 (2008)
- Howe S.J., Thrasher A.J. i wsp.: Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143–3150 (2008)
- Hyde S.C., Gill D.R. i wsp.: CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat. Biotechnol. 26, 549–551 (2008)
- Jiao S., Acsadi G., Jani A., Felgner P.L., Wolff J.A.: Persistance of plasmid DNA and expression in rat brain cells in vivo. Exp. Neurol. 115, 400–413 (1992)
- Jones P.A., Takai D.: The role of DNA methylation in mammalian epigenetics. Science, 293, 1068–1070 (2001)
- Kitagawa T., Iwazawa T., Robbins P., Lotze M., Tahara H.: Advantages and limitations of particle-mediated transfection (gene gun) in cancer immuno-gene therapy using IL-10, IL-12 or B7-1 in murine tumor models. J. Gene Med. 5, 958–965 (2003)
- Koike H., Ishida A., Hayashi T., Shimamura M., Mizuno S., Nakamura T., Iida H., Ogihara T., Kaneda Y., Morishita R.: Injection of HGF plasmid cDNA to prevent manifestation of Parkinson disease: a preclinical study using a primate model. Open Gene Ther. J. 2, 38–44 (2009)
- Koike H., Morishita R., Iguchi S., Aoki M., Matsumoto K., Nakamura T., Yokoyama C., Tanabe T., Ogihara T., Kaneda Y.: Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J. 17, 779–781 (2003)
- Kosovac D., Wild J., Ludwig C., Meissner S., Bauer A.P., Wagner R.: Minimal doses of a sequence-optimized transgene mediate high-level and long-term EPO expression in vivo: challenging CpG-free gene design. Gene Ther. 18, 189–198 (2011)
- Krieg A.M.: CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709–760 (2002)
- Krieg A.M., Wu T., Weeratna R., Efler S.M., Love-Homan L., Yang L., Yi A.K., Short D., Davis H.L.: Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. USA, 95, 12631–12636 (1998)
- Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374, 6546–6549 (1995)
- Kukuła K., Rużyłło W. i wsp.: Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am. Heart J. 161, 581–589 (2011)
- Lara A.R., Ramirez O.T.: Plasmid DNA production for therapeutic applications. Methods Mol. Biol. 824, 271–303 (2012)
- Larsen M.D., Griesenbach U., Goussard S., Gruenert D.C., Geddes D.M., Scheule R.K., Cheng S.H., Courvalin P., Grillot-Courvalin C., Alton E.W.: Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli. Gene Ther. 15, 434–442 (2008)
- Lechardeur D., Sohn K.-J., Haardt M., Joshi P.B., Monck M., Graham R.W., Beatty B., Squire J., O’Brodovich H., Lukacs G.L.: Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther. 6, 482–497 (1999)
- Loessner H., Endmann A., Leschner S., Westphal K., Rohde M., Miloud T., Hämmerling G., Neuhaus K., Weiss S.: Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo. Cell Microbiol. 9, 1529–1537 (2007)
- Madeira C., Rodrigues C.A., Reis M.S., Ferreira F.F., Correia R.E., Diogo M.M., Cabral J.M.: Nonviral gene delivery to neural stem cells with minicircles by microporation. Biomacromolecules, 14, 1379–1387 (2013)
- Magnusson T., Haase R., Schleef M., Wagner E., Ogris M. Susteined, high transgene expression in liver with plasmid vectors using optimized promoter-enhanced combinations. J. Gene Med. 13, 382–391 (2011)
- Makino H., Aoki M., Hashiya N., Yamasaki K., Azuma J., Sawa Y., Kaneda Y., Ogihara T., Morishita R.: Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler. Thromb. Vasc. Biol. 32, 2503–2509 (2012)
- Marshall W.G., Boone B.A., Burgos J.D., Gografe S.I., Baldwin M.K., Danielson M.L., Larson M.J., Caretto D.R., Cruz Y., Ferraro B., Heller L.C., Ugen K.E., Jaroszeski M.J., Heller R.: Electroporation-mediated delivery of a naked DNA plasmid expressing VEGF to the porcine heart enhances protein expression. Gene Ther. 17, 419–423 (2010)
- Miao C.H., Thompson A.R., Loeb K., Ye X.: Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol. Therapy, 3, 947–957 (2001)
- Mitsui M., Nishikawa M., Zang L., Ando M., Hattori K., Takahashi Y., Watanabe Y., Takakura Y.: Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J. Gene Med. 11, 435–443 (2009)
- Nafissi N., Alqawlaq S., Lee E.A., Foldvari M., Spagnuolo P.A., Slavcev R.A.: DNA ministrings: highly safe and effective gene delivery vectors. Mol. Ther. Nucleic Acids, DOI: 10.1038/mtna. 2014.16 (2014)
- Nafissi N., Foldvari M.: Neuroprotective therapies in glaucoma: II. Genetic nanotechnology tools. Front. Neurosci. 9, 355 DOI: 10.3389/fnins.2015.00355 (2015)
- Nafissi N., Slavcev R.: Bacteriophage recombination systems and biotechnical applications. Appl. Microbiol. Biotechnol. 98, 2841–2851 (2014)
- Oliveira P.H., Mairhofer J.: Marker-free plasmids for biotechnological applications-implications and perspectives. Trends Biotechnol. 31, 539–547 (2013)
- Palffy R., Hodosy J., Behuliak M., Resko P., Radvansky J., Celec P.: Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther. 13, 101–105 (2006)
- Ran F.A., Hsu P.D., Wright J., Agarwala V., Scott D.A., Zhang F.: Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013)
- Rauschhuber C., Noske N., Ehrhardt A.: New insights into stability of recombinant adenovirus vector genomes in mammalian cells. Eur. J. Cell Biol. 91, 2–9 (2012)
- Reyes-Sandoval A., Ertl H.C.: CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Mol. Ther. 9, 249–261 (2004)
- Ropper A.H., Gorson K.C., Gooch C.L., Weinberg D.H., Pieczek A., Ware J.H., Kershen J., Rogers A., Simovic D., Schratz-berger P., Kirchmair R., Losordo D.: Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann. Neurol. 65, 386–393 (2009)
- Rosazza C., Buntz A., Ries T., Woll D., Zumbusch A., Rols MP.: Intracellular tracking of single-plasmid DNA particles after delivery by electroporation. Mol. Therapy, 21, 2217–2226 (2013)
- Rosenberg S.A., Aebersold P., Cornetta, K., Kasid, A., Morgan R.A., Moen R., Karson E.M., Lotze M.T., Yang J.C., Topalian S.L., Merino M.J., Culver K., Miller A.D., Blaese R.M., Anderson W.F.: Gene transfer into humans — immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570–578 (1990)
- Saeed M., Martin A., Ursell P., Do L., Bucknor M., Higgins C.B., Saloner D.: MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine myocardium. Radiology, 2489, 107–118 (2008)
- Saitoh S-I., Miyake K.: Regulatory molecules required for nucleotide-sensing Toll-like receptors. Immunol. Rev. 227, 32–43 (2009)
- Sanchez-Romero M.A., Cota I., Casadesus J.: DNA methylation in bacteria: from the methyl group to the methylome. Curr. Opin. Microbiol. 25, 9–16 (2015)
- Smorawinska M., Szuplewska M., Zaleski P., Wawrzyniak P., Maj A., Plucienniczak A., Bartosik D.: Mobilizable narrow host range plasmid as natural suicide vectors enabling horizontal gene transfer among distantly related bacterial species. FEMS Microbiol. Lett. 326, 76–82 (2012)
- Spanggaard I., Gehl J. I wsp.: Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. Hum. Gene Ther.Clin. Dev. 24, 99–107 (2013)
- Staworzyńska M.J., Stachowiak R., Bielecki J.: Zastosowanie wektorów bakteryjnych w biologii molekularnej i w medycynie. Post. Mikrobiol. 50, 3–16 (2011)
- Stuchbury G., Münch G.: Optimizing the generation of stable neuronal cell lines via pre-transfection restriction enzyme digestion of plasmid DNA. Cytotechnology, 62, 189–194 (2010)
- Takahashi Y., Nishikawa M., Takakura Y.: Development of safe and effective nonviral gene therapy by eliminating CpG motifs from plasmid DNA vector. Front. Biosci. 4, 133–141 (2012)
- Taniyama Y., Azuma J., Kunugiza Y., Iekushi K., Rakugi H., Morishita R.: Therapeutic option of plasmid-DNA based gene transfer. Curr. Top. Med.Chem. 12, 1630–1637 (2012)
- Thomas C.E., Ehrhardt A., Kay M.A.: Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346–358 (2003)
- Tokunaga T., Suganuma T. i wsp.: Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer. Inst. 72, 955–962 (1984)
- Tomizawa M., Shinozaki F., Motoyoshi S., Sugiyama T., Yamamoto S., Sueishi M.: Sonoporation: gene transfer using ultrasound. World J. Methodol. 3, 39–44 (2013)
- Tros de Ilarduya C., Sun Y., Düzgüneş N.: Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci. 40, 159–170 (2010)
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (FDA): Guidance for Human Somatic Cell Therapy and Gene Therapy. (1998)
- Vandermeulen G., Marie C., Scherman C., Preat V.: New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials. Mol. Therapy, 19, 1942–1949 (2011)
- Vaughan E.E., Geiger R.C., Miller A.M., Loh-Marley P.L., Suzuki T., Miyata N., Dean D. A.: Microtubule acetylation through HDAC6 inhibition results in increased transfection efficiency. Mol. Ther. 16, 1841–1847 (2008)
- Villate-Beitia I., Puras G., Zarate J., Agirre M., Ojeda E., Pedraz J.L.: First insights into non-invasive administration routes for non-viral gene therapy (w) Gene Therapy – Principles and Challenges, red. D. Hashad, InTech, Rijeka, 2015, s. 145–177
- von Groll A., Levin Y., Barbosa M.C., Ravazzolo A.P.: Linear DNA Low Efficiency Transfection by Liposome Can Be Improved by the Use of Cationic Lipid as Charge Neutralizer. Biotechnol. Prog. 22, 1220–1224 (2006)
- Wang W., Li W., Ma N., Steinhoff G.: Non-viral gene delivery methods. Curr. Pharm. Biotechnol. 14, 46–60 (2013)
- WHO Expert Committee on Biological Standardization, 66th Report, Annex 2. WHO Press, Geneva, 2015, s. 93–130
- Wirth T., Parker N., Yla-Herttuala S.: History of gene theraphy. Gene, 525, 162–169 (2013)
- Wolff J.A., Ludtke J., Acsadi G., Williams P., Jani A.: Long-term persistence and plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1, 363–369 (1992)
- Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L.: Direct gene transfer into mouse muscle in vivo. Science, 247, 1465–1468 (1990)
- Wooddell C.I., Subbotin V.M., Sebestyén M.G., Griffin J.B., Zhang G., Schleef M., Braun S., Huss T.,Wolff J.A.: Muscle damage after delivery of naked plasmid DNA into skeletal muscles is batch dependent. Human Gene Therapy, 22, 225–235 (2011)
- Wright O., Stan G-B., Ellis T.: Building-in biosafety for synthetic biology. Microbiology, 159, 1221–1235 (2013)
- Yew N.S., Zhao H., Przybylska M., Wu I-H., Tousignant J. D., Scheule R.K., Cheng S, H. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol. Therapy, 5, 731–738 (2002)
- Yew N.S., Zhao H., Wu H-I., Song A., Tousignant J.D., Przybylska M., Cheng S.H.: Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol. Therapy, 1, 255–262 (2000)
- Zhang G., Song Y.K., Liu D.: Long-term expression of human alpha 1-antitrypsin gene in mouse liver achived by intravenous administration of plasmid DNA using hydrodynamics-based procedure. Gene Ther. 7, 1344–1349 (2000)
- Zhang H.Y., Sun S.H., Guo Y.J., Chen Z.H., Huang L., Gao Y.J., Wan B., Zhu W.J., Xu G.X., Wang J.J.: Tissue distribution of a plasmid DNA containing epitopes of foot-and-mouth disease virus in mice. Vaccine, 23, 5632–5640 (2005)